Takeaway
- Biweekly text messaging (TM) vs no TM for 36 months yielded no improvement in time to adherence failure (AF) with aromatase inhibitor (AI) therapy in women with hormone receptor (HR)-positive early breast cancer.
Why this matters
- Nonadherence to AI is common, with full adherence over a 5-year duration averaging only 50%.
- Nonadherence heightens the risk of recurrence.
Study design
- Randomized controlled trial (n=724) of TM vs no TM for a planned duration of ≥36 months.
- TM content dealt with overcoming barriers to adherence and included cues to taking action.
- Primary outcome: time to AF defined as urine AI metabolite assay satisfying any one of these outcomes:
- Funding: NIH; Breast Cancer Research Foundation; others.
Key results
- At 36 months, observed adherence did not differ between groups:
- 55.4% TM vs 55.4% no TM.
- Groups also did not differ in primary outcome, time to AF at 3 years:
- 81.9% TM vs 85.6% no TM;
- HR, 0.89 (P=.18).
- No difference between groups in 3 years:
- Self-reported time to AF:
- 10.4% TM vs 10.3% no TM;
- HR, 1.16 (P=.57).
- Site-reported time to AF:
- 21.9% TM vs 18.9% no TM;
- HR, 1.31 (P=.21).
- Self-reported time to AF:
Limitations
- Unblinded.
Malheureusement, l’accès à l’intégralité de cet article est reservé uniquement aux professionnels de santé disposant d’un compte.
Vous avez atteint la limite d'articles par visiteur
Inscription gratuite Disponible uniquement pour les professionnels de santé